INHIBIKASE THERAPEUTICS INC (IKT)

US45719W2052 - Common Stock

1.73  -0.03 (-1.7%)

After market: 1.9 +0.17 (+9.83%)

News Image
3 days ago - InvestorPlace

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024

IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

News Image
3 days ago - BusinessInsider

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (NASDAQ:IKT) just reported results for the first quarte...

News Image
4 days ago - Inhibikase Therapeutics

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET

News Image
4 days ago - Inhibikase Therapeutics

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET...

News Image
4 days ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...

News Image
10 days ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – ...

News Image
a month ago - Inhibikase Therapeutics

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage...

News Image
2 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension

News Image
2 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension

Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial Hypertension...

News Image
2 months ago - InvestorPlace

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023

IKT stock results show that Inhibikase Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 months ago - BusinessInsider

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Inhibikase Therapeutics (NASDAQ:IKT) just reported results for the fourth quart...

News Image
2 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET

News Image
2 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET...

News Image
2 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage...

News Image
3 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate

News Image
3 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylate...

News Image
3 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease -

News Image
3 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers

- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease -...

News Image
3 months ago - NewMediaWire

Dr. Milton Werner, CEO of Inhibikase Therapeutics, Inc. is Featured in an Interview With SmallCapsDaily

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image
4 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of...

News Image
4 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer

News Image
4 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli

Joseph Frattaroli to retire at end of 1Q24; Garth Lees-Rolfe, Vice-President of Finance, to be promoted to Chief Financial Officer...

News Image
5 months ago - Inhibikase Therapeutics

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage...